Szumny Dorota, Szeląg Adam
Department of Pharmacology, Wroclaw Medical University, ul. Mikulicza-Radeckiego 2, PL 50-345, Wrocław, Poland,
Graefes Arch Clin Exp Ophthalmol. 2014 Jun;252(6):917-23. doi: 10.1007/s00417-014-2623-5. Epub 2014 Apr 5.
The aim of this study was to assess the influence of propranolol, nebivolol, and carvedilol on intraocular pressure and blood flow in vessels of rabbit's (New Zealand White) eyeball.
The study was carried out on New Zealand white rabbits. Intraocular pressure was measured with the applanation tonometer Möller-Wedel and Icare; blood flow was measured with Doppler Laser Blood Flow Monitor MBD3.
Following a single administration into a conjunctival sac, all drugs decreased intraocular pressure. Iris blood flow was decreased following administration of propranol, but increased by nebivolol and carvedilol. After single and repeated oral administration of nebivolol and carvedilol an IOP decrease was demonstrated, but with no effect of all applied doses on iris or retina/choroid blood flow.
Studies performed on an animal model indicate that it is possible to reduce the intraocular pressure and increase ocular blood flow in humans, following topical administration of carvedilol and nebivolol. Confirmation of those results in clinical trials may lead to development of a new anti-glaucoma treatment. Further clinical studies of long-term nebivolol and carvedilol are recommended. They are necessary for evaluation of usefulness of those drugs for selected groups of patients, for example those with glaucoma and arterial hypertension.
本研究旨在评估普萘洛尔、奈必洛尔和卡维地洛对兔(新西兰白兔)眼球内眼压及血管血流的影响。
该研究以新西兰白兔进行。使用Möller-Wedel压平眼压计和Icare眼压计测量眼压;使用多普勒激光血流监测仪MBD3测量血流。
经结膜囊单次给药后,所有药物均降低了眼压。普萘洛尔给药后虹膜血流减少,但奈必洛尔和卡维地洛使其增加。单次及重复口服奈必洛尔和卡维地洛后眼压降低,但所有给药剂量对虹膜或视网膜/脉络膜血流均无影响。
在动物模型上进行的研究表明,局部应用卡维地洛和奈必洛尔后有可能降低人类眼压并增加眼内血流。临床试验中对这些结果的证实可能会促成一种新的抗青光眼治疗方法的开发。建议对奈必洛尔和卡维地洛进行进一步的长期临床研究。这对于评估这些药物对特定患者群体(如青光眼和动脉高血压患者)的有效性是必要的。